New York, NY -- (SBWIRE) -- 02/01/2014 -- To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
StockMarketIntel.com issues a special report on the following stocks: Edwards Lifesciences Corp (NYSE:EW), BioScrip Inc (NASDAQ:BIOS), C.R. Bard, Inc. (NYSE:BCR), ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)
Edwards Lifesciences Corp (NYSE:EW) declined -0.55%, trading on 1.51 million shares, to end the trade at $65.12. The stock changed hands in a range of $64.08 to $65.29, bringing its market capitalization to about $7.31 billion. If we look at its trading history of the past 52 weeks, the share price suffered a low of $60.62 and was moved to the maximum level of $93.98. Edwards Lifesciences Corporation (Edwards Lifesciences) is focused on technologies that treat structural heart disease and critically ill patients. A pioneer in the development and commercialization of heart valve products, Edwards Lifesciences is the manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve.
Will EW Get Buyers Even After The Recent Rally? Find Out Here
BioScrip Inc (NASDAQ:BIOS) declined -0.47%, to complete the trading session at $8.51, with a total volume of 1.51 million shares. The stock, on average, trades on a volume of 1.41 million shares. It floated in a range of $8.40 to $8.68 during the last trading session, with a beta value of 1.45. Its market capitalization now moved to about $579.61 million. In the past 52 weeks, the share price has not declined below $5.61 and above $17.42. BioScrip, Inc. (BioScrip) is a provider of pharmacy and home health services, which partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and the delivery of prescription medications and home health services.
Will BIOS Bounce Back After yesterday’s Sharp Sell off? Find Out Here
C.R. Bard, Inc. (NYSE:BCR) recorded a fall of -1.09% and was in a range of $125.53-$131.26 before closing at $129.59. The stock completed the day with a total volume of 1.48 million shares, versus an average volume of 604,032 shares. The share price hit its 52-week low of $97.14 and $141.02 was the best price. C. R. Bard, Inc. (Bard) is engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. As of December 31, 2011, the Company sold a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Is it the Right to Grab BCR after the Recent Slump? Get Free Trend Analysis Here
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) added 0.85% yesterday, bringing its market capitalization around $68.51 million. The share price, after opening at $1.18, made a high of $1.25 and hovered above $1.16 to end the day at $1.20. The total number of shares that changed hands during the session was 1.47 million shares, as compared to average trading volume of 4.14 million shares. ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies.
What was the Moving Force behind IMUC on Bullish Run? Read This Research Report
To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)